mutation-specific cancer treatment

FinalDose is developing a programmable drug platform that uses DNA sequence recognition to identify and destroy cancer cells while leaving healthy cells untouched, starting with a modality aimed at all cancers. Founded in 2025 and based in San Francisco, the company is backed by Y Combinator (Spring 2026). Core Data Grid Metric Details Funding Round…